tbuckley/cabot-search huggingface dataset:
Early Dose Intensity Is Critical in Patients with Aggressive Lymphoma: A Randomized study Comparing Identical Doses of Cyclophosphamide, Adriamycin, Vincristine, Etoposide, and Prednisolone given as 4 or 6 cycles followed by Repetitive Transplantation of Stem Cells (Mega-CHOEP).
Authors: Bertram Glass, Marita Kloess, Marcel Reiser, Wolfgang E. Berdel, Anthony D. Ho, Lorenz Truemper, Marcus Loeffler, Michael Pfreundschuh, Norbert Schmitz
Journal: Blood (2004)
Transcriptome Analysis Revealed the Entire Genetic Understanding of Pediatric Acute Myeloid Leukemia with a Normal Karyotype
Authors: Norio Shiba, Kenichi Yoshida, Yuichi Shiraishi, Shiraishi Yuichi, Yusuke Hara, Genki Yamato, Taeko Kaburagi, Masashi Sanada, Kentaro Ohki, Myoung-Ja Park, Daisuke Tomizawa, Kenichi Chiba, Hiroko Tanaka, Manabu Sotomatsu, Hirokazu Arakawa, Keizo Horibe, Takashi Taga, Souichi Adachi, Akio Tawa, Satoru Miyano, Seishi Ogawa, Yasuhide Hayashi
Journal: Blood (2016)
Induction and Maintenance Therapy for Patients with Mycosis Fungoidus (MF) and Sezary Syndrome (SS) in Large Cell Transformation Phase.
Authors: Yulia E Vinogradova, Irina Lucenko, Irina Kaplansky, Lyuba Varticovski, Nikita E Shklovskiy-Kordi, Alexandra Kremenetskya, Andrei Vorobjov
Journal: Blood (2009)
Genetic Reconstruction of Follicular Lymphoma Evolutions: Sμ Mutations Studies Suggest Two Progression Patterns, Early Direct or Late from FL “Stem Cells”.
Authors: Philippe Ruminy, Fabrice Jardin, Françoise Parmentier, Nathalie Contentin, Gérard Buchonnet, Herve Tilly, Christian Bastard
Journal: Blood (2007)
Common Fragile Site Gene FRA16D WWOX (WW domain containing oxidoreductase) Is Frequently Altered in Plasma Cells of Multiple Myeloma and MGUS, Possibly Related to Disease Development
Authors: Yoshiko Sasaki, Hiroshi Handa, Noriyuki Takahashi, Hikaru Hattori, Takayuki Saitoh, Yohei Osaki, Morio Matsumoto, Atsushi Isoda, Morio Sawamura, Akio Saito, Akihiko Yokohama, Hiromi Koiso, Takeki Mitsui, Norifumi Tsukamoto, Yoshihisa Nojima, Hirokazu Murakami
Journal: Blood (2011)
Crebbp Mutations Disrupt Dynamic Enhancer Acetylation in B-Cells, Enabling HDAC3 to Drive Lymphomagenesis
Authors: Hsia-Yuan Ying, Yanwen Jiang, Ana Ortega-Molina, Huimin Geng, Dylan McNally, Ling Wang, Ashley Doane, Xabier Agirre, Haiying Ju, David Poloway, Matt Teater, Sara Parsa, Daisuke Ennishi, David W Scott, Rita Shaknovich, Randy D. Gascoyne, Wayne Tam, Olivier Elemento, Hans-Guido Wendel, Ari Melnick
Journal: Blood (2016)
Prospective Multicentric Survey On Pulmonary Hypertension (PH) in Adults with Sickle Cell Disease.
Authors: Dora Bachir, Florence Parent, Laila Hajji, Jocelyn Inamo, Gylna Loko, Francois Lionnet, Françoise Driss, Laurent Savale, Bernard Maitre, Robert Girot, Gerald Simonneau, Frederic Galacteros
Journal: Blood (2009)
Optimal Treatment Strategy with Nilotinib for Patients with Newly Diagnosed Chronic Myelogenous Leukemia in the Chronic Phase Based on Early Achievement of Deep Molecular Response (MR4.5) : First Report from N-Road, a Phase II Study in Japan
Authors: Kaichi Nishiwaki, Kei-Ji Sugimoto, Shigehisa Tamaki, Junichi Hisatake, Hisayuki Yokoyama, Tadahiko Igarashi, Atsushi Shinagawa, Takeaki Sugawara, Satoru Hara, Kazuhisa Fujikawa, Seiichi Shimizu, Yujiri Toshiaki, Arinobu Tojo, Hisashi Wakita
Journal: Blood (2016)
Dexamethasone+Thalidomide (Dex/Thal) Compared to VAD as a Pre-Transplant Treatment in Newly Diagnosed Multiple Myeloma (MM): A Randomized Trial.
Authors: Margaret Macro, Marine Divine, Yurdagul Uzunhan, Arnaud Jaccard, Didier Bouscary, Veronique Leblond, Maud Janvier, Philippe Genet, Sylvie Castaigne, Bruno Royer, Christian Allard, Sylvie Chevret, Jean-Paul Fermand
Journal: Blood (2006)
Primitive Erythropoiesis and Osteogenesis Are Differentially Impaired In Rpl5 and Rps19 Mutant Murine Embryonic Stem Cell Models Of Diamond Blackfan Anemia
Authors: Brian M. Dulmovits, Sharon A. Singh, Tracie Goldberg, Sebastien Didier, Jeffrey M. Lipton, Lionel Blanc, Johnson M. Liu
Journal: Blood (2013)
Alisertib-Induced Polyploidy and Senescence in DH/DP-DLBCL Is Abrogated By Synthetic Lethal Interactions with Ibrutinib and Rituximab
Authors: Shariful Islam, Wenqing Qi, Carla Morales, Laurence Cooke, Manjari Pandey, Catherine M. Spier, Daruka Mahadevan
Journal: Blood (2016)
CD5-Negative Monoclonal B-Cell Lymphocytosis (MBL) Is Detectable In 9% of Adults Aged Over 40 but Phenotypes Associated with Clinically Common Non-Hodgkin Lymphomas Are Infrequent (&lt;2%)
Authors: Andy C Rawstron, Chi Doughty, Ruth M de Tute, Fiona Bennett, Selina Denman, Peter Hillmen, Andrew Jack
Journal: Blood (2010)
Children and Adults with Steroid-Refractory Acute Graft-Versus-Host Disease Respond to Treatment with the Mesenchymal Stroma Cell Preparation "MSC-FFM": Treatment Results for 92 Consecutive Patients
Authors: Peter Bader, Selim Kuci, Zyrafete Kuci, Shahrzad Bakhtiar, Oliver Basu, Gesine Bug, Michael Dennis, Johann Greil, Aniko Barta, Krisztián Kallay, Peter Lang, Giovanna Lucchini, Raj Pol, Ansgar Schulz, Karl-Walter Sykora, Irene Teichert von Luettichau, Grit Herter-Sprie, Mohammad Ashab Uddin, Philip Jenkin, Abdulrahman Alsultan, Jochen Büchner, Jerry Stein, Agnes Kelemen, Andrea Jarisch, Jan Soerensen, Emilia Salzmann-Manrique, Martin Hutter, Richard Schaefer, Erhard Seifried, Shankara Paneesha, Igor Novitzky-Basso, Aharon Gefen, Neta Nevo, Gernot Beutel, Paul G. Schlegel, Thomas Klingebiel, Halvard Bonig
Journal: Blood (2018)
Parallel Concerted Evolution of Ribosomal Protein Genes in Fungi and Its Adaptive Significance
Authors: Alison Mullis, Zhaolian Lu, Yu Zhan, Tzi-Yuan Wang, Judith Rodriguez, Ahmad Rajeh, Ajay Chatrath, Zhenguo Lin
Journal: Molecular Biology and Evolution (2019)

Ribosomal protein (RP) genes encode structural components of ribosomes, the cellular machinery for protein synthesis. A single functional copy has been maintained in most of 78-80 RP families in animals due to evolutionary constraints imposed by gene dosage balance. Some fungal species have maintained duplicate copies in most RP families. The mechanisms by which the RP genes were duplicated and maintained and their functional significance are poorly understood. To address these questions, we identified all RP genes from 295 fungi and inferred the timing and nature of gene duplication events for all RP families. We found that massive duplications of RP genes have independently occurred by different mechanisms in three distantly related lineages: budding yeasts, fission yeasts, and Mucoromycota. The RP gene duplicates in budding yeasts and Mucoromycota were mainly created by whole genome duplication events. However, duplicate RP genes in fission yeasts were likely generated by retroposition, which is unexpected considering their dosage sensitivity. The sequences of most RP paralogs have been homogenized by repeated gene conversion in each species, demonstrating parallel concerted evolution, which might have facilitated the retention of their duplicates. Transcriptomic data suggest that the duplication and retention of RP genes increased their transcript abundance. Physiological data indicate that increased ribosome biogenesis allowed these organisms to rapidly consume sugars through fermentation while maintaining high growth rates, providing selective advantages to these species in sugar-rich environments.
Update of a Phase I Study of Sorafenib in Patients with Refractory/Relapsed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome.
Authors: John Delmonte, Hagop M. Kantarjian, Michael Andreeff, Stefan Faderl, John J. Wright, Weiguo Zhang, Marina Konopleva, Srdan Verstovsek, Gautam Borthakur, Farhad Ravandi, Jorge Cortes
Journal: Blood (2007)
KN100: Results from Japanese patients with advanced recurrent ovarian cancer treated with pembrolizumab monotherapy
Authors: Koji Matsumoto, Shin Nishio, Kazuhiro Takehara, Naoki Kawamura, Kosei Hasegawa, Nobuhiro Takeshima, Daisuke Aoki, Shoji Kamiura, Atsushi Arakawa, Eiji Kondo, Tomoko Hirakawa, Keiko Yamamoto, Shi Rong Han, Karen Stein, Stephen Keefe, Jonathan Lederman, Ursula Matulonis, Keiichi Fujiwara
Journal: Annals of Oncology (2019)
MDS-Derived Stromal Cells Exhibit Altered Gene Expression and Support The Engraftment Of lin-CD34+CD38- Disease-Initiating Stem Cells In a Xenograft Model Of Lower Risk MDS
Authors: Hind Medyoup, Maximilian Mossner, Johann-Christoph Jann, Florian Nolte, Christian Eisen, Amelie Lier, Verena Nowak, Bettina Zens, Corinna Klein, Katja Müdder, Stephanie Fey, Julia Obländer, Jovita Vogler, Alice Fabarius, Eva Riedl, Henning Roehl, Alexander Kohlmann, Marita Staller, Claudia Haferlach, Müller Nadine, John Thilo, Georgia Metzgeroth, Wolf-Karsten Hofmann, Andreas Trumpp, Daniel Nowak
Journal: Blood (2013)
Myeloablative Chemo-Conditioning for First Hematopoietic STEM CELL Transplantation in Children with ACUTE Lymphoblastic Leukemia in First or Second Remission
Authors: Christina Peters, Jean-Hugues Dalle, Stelios Graphakos, Petr Sedlacek, Antonio Campos, M. Akif Yesilipek, Jacek Wachowiak, Arjan C. Lankester, Andrea Pession, Amir Ali Hamidieh, Marianne Ifversen, Jochen Büchner, Gergely Krivan, Franca Fagioli, Arnaud Dalissier, Myriam Labopin, Peter Bader
Journal: Blood (2014)
It Is Easix to Predict Non-Relapse Mortality (NRM) of Allogeneic Stem Cell Transplantation (alloSCT)
Authors: Thomas Luft, Axel Benner, Sonata Jodele, Christopher E. Dandoy, Rainer F. Storb, Ted A. Gooley, Brenda M. Sandmaier, Aleksandar Radujkovic, Anthony D. Ho, Peter Dreger, Olaf Penack
Journal: Blood (2016)
Persistent Centre Effect but Improvement of Leukemia-Free Survival of HLA Identical Hematopoietic Stem Cell Transplantation for Adults with AML in First CR in Europe over the Period 1987–2005 an Analysis on Behalf of the ALWP of EBMT.
Authors: Sandrine Katsahian, Myriam Labopin, Francesco Frassoni, Vanderson Rocha, Sylvie Chevret
Journal: Blood (2006)
CCL3 Regulates Normal Hematopoiesis but Is Not Essential for the Maintenance of a Long-Term Engrafting Hematopoietic Stem Cell
Authors: Rhonda J. Staversky, Lila Yang, Alexandra N. Goodman, Mary A Georger, Michael W. Becker, Laura M. Calvi, Benjamin J. Frisch
Journal: Blood (2016)
Immune-Based Therapies Targeting Mage-A4 for Relapsed/Refractory Hodgkin's Lymphoma After Stem Cell Transplant.
Authors: Conrad Russell Y. Cruz, Ann M. Leen, Ulrike Gerdemann, Anne S. Christin, Tamara Tripic, Jessica Shafer, Anas Younes, Terzah M. Horton, Elizabeth J. Shpall, Helen E. Heslop, Cliona M. Rooney, Catherine M. Bollard
Journal: Blood (2009)
Baseline neutrophil to lymphocyte ratio is predictor of longer OS of metastatic BC patients treated with eribulin
Authors: Shota Kusuhara, Takahiro Kogawa, Mototsugu Shimokawa, Sumito Shingaki, Yumi Fujimoto, Kenichi Harano, Nobuaki Matsubara, Yoichi Naito, Ako Hosono, Hirofumi Mukai, Toru Mukohara
Journal: Annals of Oncology (2019)
Crude and Age-Adjusted Ph+/Bcr-Abl+ Chronic Myeloid Leukemia Incidence Rate in St. Petersburg and Leningrad Region Between 2006–2011
Authors: Kudrat Abdulkadyrov, Elza Lomaia, Natalia Lazorko, Vasiliy Shuvaev, Alla Abdulkadyrova, Irina Martinkevich, Elena Usacheva, Vera Udalieva, Irina Zotova, Elena Machulaitene, Natalia Ilina, Elena Karyagina, Irina Kholopova, Ekaterina Romanova, Eugenia Sbityakova, Tatiana Shneider, Andrey Zaritskey
Journal: Blood (2012)
Palliative cancer therapy during end of life at a regional cancer center in Norway in 2005 and 2009.
Authors: Mari Aas Gynnild, Malin Anshushaug, Stein Kaasa, Anne Kvikstad, Bjørn Henning Grønberg
Journal: Journal of Clinical Oncology (2012)

9040 Background: With increasing number of available therapies, there is a risk that patients (pts) are overtreated. Palliative cancer therapy is mostly recommended for pts with good Performance Status (PS). In one study, 42 % of pts received chemotherapy (CTx) during the last 30 days of life – suggesting that this may not always be the case. Methods: All pts who, according to the national registry, died from cancer in our region in 2005 and 2009 were analyzed. Data were collected from individual medical records. Endpoints: Time from the end of palliative cancer therapy until death. Whether there were differences depending on age; type of cancer; year of death or if they were seen at a palliative care unit (PCU). PS when the last cancer therapy was initiated. Results: 616 pts died in 2005; 599 in 2009. We excluded 495 pts: No cancer therapy (n=260); no information of cancer (n=101); last therapy with curative intention (n=83); hematological malignancy (n=51). Median age 71 (6 - 99); 49 % men; median overall survival from diagnosis: 16.9 mos. Last therapy was radiotherapy (RT): 31 %; CTx: 40 %; hormonal: 15 %; surgery: 11 %. 4 % died from treatment complications. Median time from start of last CTx or RT until death: 100 days; from end of last CTx or RT: 63 days. Younger pts received more CTx and RT in the last 30 days: Age &lt; 60: 28 %; 60-70: 23 % and 70+: 12 % (p&lt;.001). The table shows the use of CTx and RT the last 30 and 14 days for the most common cancers. Among those who got CTx in the last 30 days (n=74); 54 % had PS 2; 14 % PS 3-4. Among those who got RT in the last 30 days (n=61), 31 % had PS 2; 54 % PS 3-4. Of the 49 % referred to the PCU, fewer received CTx or RT in the last 30 days (PCU: 14 %, no PCU: 22 %; p=.002) and 14 days (PCU: 5 %, no PCU: 12 %; p&lt;.001). Conclusions: Many pts received cancer therapy the last month of life. The percentage varies with age, cancer type and was lower in 2009 than in 2005. Pts seen at the PCU received less CTx and RT. Many pts had a poorer PS at the start of last cancer therapy than recommended. [Table: see text]
Different Thresholds of Serum Ferritin Levels for Prediction of Liver Iron Concentration in Hemoglobinopathies
Authors: Angela Vitrano, Giuseppina Calvaruso, Lorenzo Tesè, Francesco Gioia, Filippo Cassarà, Saveria Campisi, Franco Butera, Valeria Commendatore, Michele Rizzo, Vincenzo Santoro, Valeria Cigna, Alessandra Quota, Sabrina Bagnato, Crocetta Argento, Carmelo Fidone, Dario Schembari, Calogera Gerardi, Filippo Barbiera, Giuseppe Bellissima, Giovanni Giugno, Gesualdo Polizzi, Rosamaria Rosso, Giovanna Abbate, Vincenzo Caruso, Elisabetta Chiodi, Maria Rita Gamberini, Benedetta Giorgi, Maria Caterina Putti, Maria Rosaria De Ritis, Aldo Filosa, Esther Natalie Oliva, Nicola Arcadi, Massimiliano Sacco, Rosario Di Maggio, Laura Mistretta, Veronica Di Salvo, Antonino Giangreco, Aurelio Maggio
Journal: Blood (2015)
Effect of Methylprednisolone or Zoledronic Acid on Resolution of Active Charcot Neuroarthropathy in Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study
Authors: Liza Das, Anil Bhansali, Mahesh Prakash, Edward B. Jude, Ashu Rastogi
Journal: Diabetes Care (2019)

Charcot neuroarthropathy (CN) is a complex syndrome affecting people with diabetes and peripheral neuropathy but preserved vascularity. Without early intervention, active CN may have long-term consequences (1). Recent studies suggest the role of proinflammatory cytokines, particularly tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), in mediating inflammatory osteolysis by activating the receptor activator of nuclear factor-κB (RANKL-NF-κB) pathway, thus perpetuating bone loss in an insensate foot with active CN (2,3). The goal of treatment in active CN is therefore to curtail the ongoing inflammation and/or osteolysis. Antiresorptive agents to inhibit osteolysis have been used with modest success (4,5), but anti-inflammatory agents have not been evaluated for CN. We studied the efficacy of methylprednisolone (MP) or zoledronic acid (ZA) in comparison with placebo in active CN along with total contact cast (TCC) as the primary modality.

Included participants had a clinical diagnosis of active CN (erythematous and swollen) with a foot temperature difference exceeding 2°C by infrared dermal thermometry (FLIR Systems, Inc., Orlando, FL) compared with a similar site on the opposite foot, substantiated by X-ray and/or MRI. Bone turnover markers (BTMs) P1NP and CTX (Elecsys; Roche Diagnostics, Mannheim, Germany) were estimated by electrochemiluminescence …
Long Term Outcome After Low Dose TBI Based Conditioning Hematopoietic Stem Cell Transplantation (HSCT) From Related and Unrelated Donors for Older Patients with AML
Authors: Dietger Niederwieser, Leo F Verdonck, Jan J Cornelissen, Michael Cross, Rainer Krahl, Thoralf Lange, Vladan Vucinic, Georg Franke, Haifa K. Al-Ali, Gert Ossenkoppele, Georg Maschmeyer, Gottfried Doelken, Mathias Freund, Norma Peter, Marc Boogaerts, Alois Gratwohl, Harry C. Schouten, Bob Lowenberg
Journal: Blood (2011)
Molecular Remission After Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Consolidation Therapy Following Double Autologous Transplantation for Multiple Myeloma: Results of a Qualitative and Quantitative Analysis
Authors: Carolina Terragna, Elena Zamagni, Maria Teresa Petrucci, Sandra Durante, Francesca Patriarca, Franco Narni, Claudia Crippa, Ausilia Gorgone, Tommaso Caravita, Giulia Perrone, Chiara Nozzoli, Luciano Masini, Vincenzo Callea, Immacolata Attolico, Claudia Cellini, Sara Bringhen, Antonio Ledda, Vittorio Montefusco, Marina Martello, Giovanni Martinelli, Michele Baccarani, Michele Cavo
Journal: Blood (2010)
Prognostic Value of Minimal Residual Disease by Real-Time Quantitative PCR in AML with CBFB-MYH11 Rearrangement: The French Experience.
Authors: Romain Guièze, Aline Renneville, Jean-Michel Cayuela, Raouf Ben Abdelali, Nicolas Boissel, Marie-Thérèse Rubio, Françoise Mazingue, Elizabeth A. Macintyre, François Sigaux, Pierre Fenaux, Hervé Dombret, Claude Preudhomme
Journal: Blood (2007)
Benchmark of computational methods for predicting microRNA-disease associations
Authors: Zhou Huang, Leibo Liu, Yuanxu Gao, Jiangcheng Shi, Qinghua Cui, Jianwei Li, Yuan Zhou
Journal: Genome biology (2019)

A series of miRNA-disease association prediction methods have been proposed to prioritize potential disease-associated miRNAs. Independent benchmarking of these methods is warranted to assess their effectiveness and robustness.Based on more than 8000 novel miRNA-disease associations from the latest HMDD v3.1 database, we perform systematic comparison among 36 readily available prediction methods. Their overall performances are evaluated with rigorous precision-recall curve analysis, where 13 methods show acceptable accuracy (AUPRC > 0.200) while the top two methods achieve a promising AUPRC over 0.300, and most of these methods are also highly ranked when considering only the causal miRNA-disease associations as the positive samples. The potential of performance improvement is demonstrated by combining different predictors or adopting a more updated miRNA similarity matrix, which would result in up to 16% and 46% of AUPRC augmentations compared to the best single predictor and the predictors using the previous similarity matrix, respectively. Our analysis suggests a common issue of the available methods, which is that the prediction results are severely biased toward well-annotated diseases with many associated miRNAs known and cannot further stratify the positive samples by discriminating the causal miRNA-disease associations from the general miRNA-disease associations.Our benchmarking results not only provide a reference for biomedical researchers to choose appropriate miRNA-disease association predictors for their purpose, but also suggest the future directions for the development of more robust miRNA-disease association predictors.
Newly Diagnosed Multiple Myeloma (MM) Patients Treated With Lenalidomide Induction and Maintenance Show a Low Incidence Of Second Primary Malignancies (SPMs)
Authors: Annamaria Brioli, Charlotte Pawlyn, Walter Gregory, Samantha Hinsley, Samantha Marshall, Jindriska Lindsay, Claire Chapman, Gordon Cook, Donald Milligan, Michele Cavo, Graham H Jackson, Nigel Russel, Faith E Davies, Gareth J Morgan
Journal: Blood (2013)
Variation in Health-Related Quality of Life by ECOG Performance Status and Fatigue Among Patients with Chronic Lymphocytic Leukemia
Authors: Chris L. Pashos, Christopher R Flowers, Mark Weiss, Nicole Lamanna, Charles M Farber, Thomas J. Kipps, Susan Lerner, Neil Kay, Jeff Porte Sharman, David L. Grinblatt, Ian W. Flinn, Mark Kozloff, Arlene S Swern, Zeba M. Kahn, Thomas K. Street, Gale Harding, Kristen A Sullivan, Michael J Keating
Journal: Blood (2011)
Distinctive Patterns of Intraclonal Diversification In IGHV1-2*04 Immunoglobulin Receptors of Patients with Splenic Marginal Zone Lymphoma: A of Ongoing Interactions with Antigen?
Authors: Vasilis Bikos, Evangelia Stalika, Nikos Darzentas, Maria Karypidou, Panagiotis Baliakas, Zadie Davis, Sarah Hockley, Alexandra Traverse-Glehen, Patricia Algara, George Kanellis, Manuela Mollejo, Alessandra Santoro, Antonis Dagklis, David Bosler, George Bourikas, Athanasios Tsaftaris, Achilles Anagnostopoulos, Emilio Iannitto, Maurilio Ponzoni, Francoise Berger, Pascale Felman, Ahmet Dogan, Paolo Ghia, Chrysoula Belessi, Theodora Papadaki, David Gonzalez, Estella Matutes, Miguel Angel Piris, David Oscier, Kostas Stamatopoulos
Journal: Blood (2011)
Ultra-Deep Sequencing of De Novo IGHV Mutations in Activated CLL Cells: Evidence for Activation-Induced Deaminase Function.
Authors: Piers E.M. Patten, Thomas MacCarthy, Xiao-Jie Yan, Jonathan E. Kolitz, Steven L. Allen, Jacqueline C. Barrientos, Kanti R. Rai, Nicholas Chiorazzi, Charles C. Chu
Journal: Blood (2012)
Risk of Developing Parkinson Disease in Bipolar Disorder
Authors: Patrícia R. Faustino, Gonçalo S. Duarte, Inês Chendo, Ana Castro Caldas, Sofia Reimão, Ricardo M. Fernandes, José Vale, Michele Tinazzi, Kailash Bhatia, Joaquim J. Ferreira
Journal: JAMA Neurology (2019)

<h3>Importance</h3> Parkinson disease (PD) manifests by motor and nonmotor symptoms, which may be preceded by mood disorders by more than a decade. Bipolar disorder (BD) is characterized by cyclic episodes of depression and mania. It is also suggested that dopamine might be relevant in the pathophysiology of BD. <h3>Objective</h3> To assess the association of BD with a later diagnosis of idiopathic PD. <h3>Data Sources</h3> An electronic literature search was performed of Cochrane Controlled Register of Trials, MEDLINE, Embase, and PsycINFO from database inception to May 2019 using the terms<i>Parkinson disease</i>,<i>bipolar disorder</i>, and<i>mania</i>, with no constraints applied. <h3>Study Selection</h3> Studies that reported data on the likelihood of developing PD in BD vs non-BD populations were included. Two review authors independently conducted the study selection. <h3>Data Extraction and Synthesis</h3> Two review authors independently extracted study data. Data were pooled using a random-effects model, results were abstracted as odds ratios and 95% CIs, and heterogeneity was reported as<i>I</i><sup>2</sup>. <h3>Main Outcome and Measures</h3> Odds ratios of PD. <h3>Results</h3> Seven studies were eligible for inclusion and included 4 374 211 participants overall. A previous diagnosis of BD increased the likelihood of a subsequent diagnosis of idiopathic PD (odds ratio, 3.35; 95% CI, 2.00-5.60;<i>I</i><sup>2</sup> = 92%). A sensitivity analysis was performed by removing the studies that had a high risk of bias and also showed an increased risk of PD in people with BD (odds ratio, 3.21; 95% CI, 1.89-5.45;<i>I</i><sup>2</sup> = 94%). Preplanned subgroup analyses according to study design and diagnostic certainty failed to show a significant effect. <h3>Conclusions and Relevance</h3> This review suggests that patients with BD have a significantly increased risk of developing PD compared with the general population. Subgroup analyses suggested a possible overestimation in the magnitude of the associations. These findings highlight the probability that BD may be associated with a later development of PD and the importance of the differential diagnosis of parkinsonism features in people with BD.
Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia Harboring t(7;11)(p15;p15)
Authors: Kaito Harada, Noriko Doki, Jun Aoki, Jinichi Mori, Shinichiro Machida, Yuho Najima, Naoyuki Uchida, Takahiro Fukuda, Heiwa Kanamori, Hiroyasu Ogawa, Tatsuo Ichinohe, Yoshiko Atsuta, Shingo Yano
Journal: Blood (2016)